Cholera Vaccines Market Growth, Demand and Challenges of the Key Industry Players 2024-2032
                     Global Cholera Vaccines 
Market Research and 
Forecast Report 2024-
2032
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved 
About IMARC Group
In ternat ional  Market  Analys is  Research and Consul t ing Group is  a leading adv iser  on management  
s t rategy and market  research wor ldwide.  We par tner  wi th c l ients  in  a l l  regions and indust ry  
vert ica ls  to  ident i fy  thei r  h ighest -value oppor tuni t ies,  address thei r  most  cr i t ica l  chal lenges,  and 
t ransform thei r  bus inesses.
IMARC’s in format ion products  inc lude major market ,  sc ient i f ic ,  economic and technological  
developments  for  bus iness leaders  in  pharmaceut ica l ,  indust r ia l ,  and h igh technology 
organizat ions.  Market  forecasts  and indust ry  analys is  for  b iotechnology,  advanced mater ia ls ,  
chemicals ,  food and beverage,  t ravel  and tour ism, nanotechnology and novel  process ing methods 
are at  the top of  the company’s  exper t ise.
IMARC’s ta i lored approach combines unfathomable ins ight  in to the dynamics o f  companies and 
markets wi th c lose cooperat ion at  a l l  levels  of  the c l ient  organizat ion.  This ensures that  our  c l ients 
achieve unmatchable compet i t ive advantage,  bui ld  more pro f ic ient  organizat ions,  and secure 
las t ing resul ts .
A c c o r d i n g  t o  t h e  l a t e s t  r e p o r t  b y  I M A R C  G r o u p ,  t i t l e d  " C h o le r a  V a c c i n e s  M a r k e t :  G l o b a l  
In d u s t r y  T r e n d s ,  S h a r e ,  S i z e ,  G r o w t h ,  O p p o r t u n i t y  a n d  F o r e c a s t  2 0 2 4 -
2 0 3 2 , "  t h e  g l o b a l  c h o l e r a  v a c c i n e s  m a r k e t  s i z e  r e a c h e d  U S $  5 . 4  M i l l i o n  i n  2 0 2 3 .
F a c to rs  A f fe c t in g  th e  G ro w th  o f  th e  C h o le ra  V a c c in e s  In d u s t ry :
Report P u b l ic  H e a l th  D e ma n d  a n d  O u tb r e a k s :T h e  g r o w th  o f  t h e  c h o l e r a  v a c c i n e s  i n d u s t r y  i s  h e a v i l y  i n f l u e n c e d  b y  t h e  f r e q u e n c y  a n d  
s e v e r i t y  o f  c h o l e r a  o u tb r e a k s .  C h o l e r a  r e m a i n s  a  s i g n i f i c a n t  p u b l i c  h e a l t h  c o n c e r n  i n  m a n y  
Highlight and p a r t s  o f  t h e  w o r l d ,  p a r t i c u l a r l y  i n  r e g i o n s  w i t h  i n a d e q u a t e  s a n i t a t i o n  a n d  a c c e s s  t o  c l e a n  w a t e r .  T h e  r e c u r r i n g  n a tu r e  o f  o u t b r e a k s  i n  c o u n t r i e s  s u c h  a s  Y e m e n ,  H a i t i ,  a n d  s e v e r a l  
A f r i c a n  n a t i o n s  u n d e r s c o r e s  t h e  u r g e n t  n e e d  f o r  e f f e c t i v e  v a c c i n a t i o n  p r o g r a m s .  
Description A s  o u t b r e a k s  c o n t i n u e  t o  c a u s e  h i g h  m o r b i d i t y  a n d  m o r t a l i t y ,  e s p e c i a l l y  i n  v u l n e r a b l e  p o p u l a t i o n s ,  t h e r e  i s  a  g r o w i n g  d e m a n d  f o r  p r e v e n t i v e  me a s u r e s ,  i n c l u d i n g  v a c c i n e s .  T h i s  
d e m a n d  d r i v e s  i n v e s tm e n t s  i n  v a c c i n e  d e v e l o p m e n t  a n d  d i s t r i b u t i o n ,  f o s t e r i n g  i n d u s t r y  
g r o w t h .  F u r t h e r m o r e ,  i n c r e a s e d  a w a r e n e s s  a n d  p r i o r i t i z a t i o n  o f  c h o l e r a  p r e v e n t i o n  b y  
g l o b a l  h e a l t h  o r g a n i z a t i o n s ,  s u c h  a s  t h e  W o r l d  H e a l t h  O r g a n i z a t i o n  ( W H O )  a n d  t h e  G l o b a l  
T a s k  F o r c e  o n  C h o l e r a  C o n t r o l  ( G T F C C ) ,  b o l s t e r  t h e  p u s h  f o r  w i d e s p r e a d  v a c c i n a t i o n  
e f f o r t s .
Advancements  in  Vaccine  Technology:
Tech no log i ca l  a dvanc em e n t s  p lay  a  c r uc ia l  r o le  i n  t h e  exp ans io n  o f  t h e  cho l e r a  
vacc ines  i ndu s t r y .  I nnova t i ons  i n  b io t echno logy  and  va cc ine  de l i ve r y  m e t hod s  h ave  
l ed  t o  t he  deve lopm e n t  o f  m or e  e f f ec t i v e  an d  ea s ie r - t o - ad m in i s t e r  v acc in es .  O r a l  
Report cho le r a  vacc i nes  ( O CVs) ,  su ch  as  D uko r a l ,  Shan cho l ,  and  E uv i ch o l ,  ha ve  im pr ov ed  im m unoge n ic i t y  an d  c an  be  adm in i s t e r ed  w i t ho u t  t he  nee d  f o r  he a l t hc a r e  
p r o f ess io na l s ,  m ak ing  m as s  v acc ina t i on  cam pa ign s  m or e  f eas ib le ,  e spec ia l l y  i n  
Highlight and r eso u r ce - l im i t e d  se t t i ng s .  
Add i t i ona l l y ,  ongo ing  r ese a r ch  i n t o  new  v acc in e  cand id a t es  an d  f o r m u la t i on s  a im s  t o  
enha nce  t he  du r a t i on  o f  im m un i t y  and  e f f ec t i vene ss  a ga ins t  d i ve r se  ch o le r a  s t r a in s .  
Description Thes e  t ech no lo g i ca l  im p r ove m en t s  e nhan ce  t he  ov e r a l l  e f f i cac y  o f  cho le r a  vacc ines  
and  r educe  p r odu c t i o n  cos t s  and  l og i s t i c a l  cha l l e nges ,  m ak i ng  va cc ines  m or e  
acce ss ib le  and  a f f o r dab le  f o r  ende m ic  r eg ion s .
In ternat ional  Funding and Suppor t :
The  ava i l ab i l i t y  o f  i n t e r na t i ona l  f und ing  an d  su ppo r t  i s  a  p i vo t a l  f ac t o r  i n  t h e  g r o w t h  
o f  t he  cho le r a  vac c ines  i n dus t r y .  La r ge - s ca le  v acc ina t i on  p r og r am s  r equ i r e  
sub s t an t i a l  f i nan c ia l  r es ou r c es ,  wh ic h  a r e  o f t e n  p r ov id ed  by  i n t e r na t io na l  dono r s ,  
gov er nm en t s ,  and  non - gove r nm en t a l  o r gan i za t i o ns  ( NG O s) .
Ins t i tu t ions  such  as  Gav i ,  t he  Vacc ine  A l l iance ,  and  the  B i l l  &  Me l inda  Gates  
Founda t ion  have  been  ins t rumenta l  in  fund ing  cho le ra  vacc ina t ion  in i t ia t i ves ,  
ensur ing  the  p rocurement  and  d is t r i bu t ion  o f  vacc ines  to  h igh - r isk  a reas .  
Add i t iona l l y ,  coord ina ted  e f fo r ts  by  g loba l  hea l th  bod ies  to  secure  vacc ine  
s tockp i les  and  respond  swi f t l y  t o  ou tb reaks  have  underscored  the  impor tance  
o f  sus ta ined  f inanc ia l  commi tment .  Such  suppo r t  f ac i l i ta tes  immed ia te  
Report ou tb reak  response  and  a ids  in  long- te rm p lann ing  and  in f ras t ruc tu re  
deve lopment  fo r  rou t ine  immun iza t ion  p rograms.  Th is  f inanc ia l  back ing  is  
essen t ia l  f o r  ma in ta in ing  and  sca l ing  up  p roduc t ion  capac i t i es ,  research ,  and  
Highlight and d is t r ibu t ion  ne tworks ,  u l t ima te ly  d r i v ing  the  indus t ry 's  g rowth .
Description Request  for  a  PDF sample  o f  th is  repor t :  
h t tps : / /www. imarcgroup .com/cho le ra -vacc ines -marke t / reques tsamp le
Report Description
Global  Cholera Vaccines Market  Trends:
The g lobal  cho lera vacc ines market  is  w i tness ing s ign i f icant  growth,  dr iven by severa l  key t rends.  
Increas ing inc idence of  cho lera outbreaks,  par t icu lar ly  in  develop ing reg ions,  has he ightened the demand 
for  e f fec t ive vacc ina t ion programs.  Bes ides th is ,  ongo ing technolog ica l  advancements ,  such as the 
development  o f  ora l  cho lera vacc ines (OCVs)  such as Dukora l ,  Shanchol ,  and Euv ichol ,  have improved 
access ib i l i ty  and admin is t ra t ion,  fac i l i ta t ing large-sca le  immunizat ion ef for ts .  Suppor t  f rom in ternat ional  
organizat ions,  inc lud ing WHO and Gav i ,  has bo ls tered funding and d is t r ibut ion,  ensur ing vacc ines reach 
h igh-r isk popula t ions.  
Addi t iona l ly ,  there is  a  growing emphas is  on prevent ive heal thcare and the in tegrat ion of  cho lera vaccines 
in to  rout ine immunizat ion schedules.  Fur thermore,  co l laborat ive e f fo r ts  between governments ,  NGOs,  and 
pr ivate  sector  p layers are a lso dr iv ing market  expans ion.  
View Report  TOC,  F igures and Tables :  ht tps: / /www.imarcgroup.com/cholera-vaccines-market
Breakup by Vaccine Type:
• Whole Cel l  V.  Cholerae O1 with Recombinant B-
Subunit
• Ki l led Oral  O1 and O139
 
Breakup by Product:
Report • Dukoral
• Shanchol
Segmentation • Vaxchora
• Euvichol  and Euvichol-Plus
• Others
Breakup by End User:
• Hospitals and Cl inics
• Research and Academic Laboratories
• Others
Breakup by Region:
• North America
Report • Asia-Pacifi c
• Europe
Segmentation • Latin America
• Middle East and Afr ica
• Astel las Pharma Inc.
• Celldex Therapeutics Inc.  (Avant 
Immunotherapeutics Inc.)
• Emergent BioSolut ions Inc.
Competitive • Eubiologics Co. Ltd.
Landscape • Johnson & Johnson
• Merck & Co. Inc.
with Key • Pfi zer Inc.
Players • PharmaChoice Canada Inc.
• Sanofi  S.A.
• Takeda Pharmaceutical  Company Limited
• Valneva SE
What was the size of the global cholera vaccines market 
in 2023?
What is the expected growth rate of the global cholera 
vaccines market during 2024-2032?
What are the key factors driving the global cholera 
vaccines market?
Key 
What has been the impact of COVID-19 on the global 
Questions cholera vaccines market?
Answered in What is the breakup of the global cholera vaccines market based on the vaccine type?
the Report What is the breakup of the global cholera vaccines 
market based on the product?
What is the breakup of the global cholera vaccines 
market based on the end user?
What are the key regions in the global cholera vaccines 
market?
Who are the key players/companies in the global 
cholera vaccines market?
1     P r e f a c e
2     S c o p e  a n d  M e t h o d o l o g y
    2 . 1     O b j e c t i v e s  o f  t h e  S t u d y
    2 . 2     S t a k e h o l d e r s
    2 . 3     D a t a  S o u r c e s
        2 . 3 . 1     P r i m a r y  S o u r c e s
        2 . 3 . 2     S e c o n d a r y  S o u r c e s
    2 . 4     M a r k e t  E s t i m a t i o n
        2 . 4 . 1     B o t t o m - U p  A p p r o a c h
Table of         2 . 4 . 2     T o p - D o w n  A p p r o a c h    2 . 5     F o r e c a s t i n g  M e t h o d o l o g y
3     E x e c u t i v e  S u m m a r y
4     I n t r o d u c t i o n
    4 . 1     O v e r v i e w
Contents     4 . 2     K e y  I n d u s t r y  T r e n d s5     G l o b a l  C h o l e r a  V a c c i n e s  M a r k e t
    5 . 1     M a r k e t  O v e r v i e w
    5 . 2     M a r k e t  P e r f o r m a n c e
    5 . 3     I m p a c t  o f  C O V I D - 1 9
    5 . 4     M a r k e t  F o r e c a s t
6      M a r k e t  B r e a k u p  b y  V a c c i n e  T y p e
    6 . 1     W h o l e  C e l l  V .  C h o l e r a e  O 1  w i t h  R e c o m b i n a n t  B - S u b u n i t
        6 . 1 . 1  M a r k e t  T r e n d s
        6 . 1 . 2  M a r k e t  F o r e c a s t
    6 . 2     K i l l e d  O r a l  O 1  a n d  O 1 3 9
        6 . 2 . 1  M a r k e t  T r e n d s
        6 . 2 . 2  M a r k e t  F o r e c a s t
7    M a r k e t  B r e a k u p  b y  P r o d u c t
    7 . 1     D u k o r a l
        7 . 1 . 1  M a r k e t  T r e n d s
        7 . 1 . 2  M a r k e t  F o r e c a s t
       
    7 . 2     S h a n c h o l
        7 . 2 . 1  M a r k e t  T r e n d s
        7 . 2 . 2  M a r k e t  F o r e c a s t
    7 . 3     V a x c h o r a
        7 . 3 . 1  M a r k e t  T r e n d s
        7 . 3 . 2  M a r k e t  F o r e c a s t
    7 . 4     E u v i c h o l  a n d  E u v i c h o l - P l u s
        7 . 4 . 1  M a r k e t  T r e n d s
        7 . 4 . 2  M a r k e t  F o r e c a s t
    7 . 5     O t h e r s
        7 . 5 . 1  M a r k e t  T r e n d s
        7 . 5 . 2  M a r k e t  F o r e c a s t
Table of 8    M a r k e t  B r e a k u p  b y  E n d  U s e r    8 . 1     H o s p i t a l s  a n d  C l i n i c s
        8 . 1 . 1  M a r k e t  T r e n d s
        8 . 1 . 2  M a r k e t  F o r e c a s t
Contents     8 . 2     R e s e a r c h  a n d  A c a d e m i c  L a b o r a t o r i e s
        8 . 2 . 1  M a r k e t  T r e n d s
        8 . 2 . 2  M a r k e t  F o r e c a s t
    8 . 3     O t h e r s
        8 . 3 . 1  M a r k e t  T r e n d s
        8 . 3 . 2  M a r k e t  F o r e c a s t
9    M a r k e t  B r e a k u p  b y  R e g i o n
    9 . 1     N o r t h  A m e r i c a
        9 . 1 . 1  U n i t e d  S t a t e s
           9 . 1 . 1 . 1  M a r k e t  T r e n d s
           9 . 1 . 1 . 2  M a r k e t  F o r e c a s t
        9 . 1 . 2  C a n a d a
           9 . 1 . 2 . 1  M a r k e t  T r e n d s
           9 . 1 . 2 . 2  M a r k e t  F o r e c a s t
F o r  m o r e  i n f o r m a t i o n ,  v i s i t :  
ht t ps : / /w ww. i ma rc gro up . c o m /c ho l e ra -va c c i nes -m a rke t / t o c
Partial List of Clients
Partial List of Clients
Disclaimer
© 2024  IMARC Al l  R ights  Reserved 
Th is  Pub l i ca t ion  and  a l l  i t ’ s  con ten ts  un less  o therw ise  men t i oned  a re  copy r i gh ted  in  the  name o f  
I n t e rna t i ona l  Marke t  Ana lys i s  Research  and  Consu l t ing  ( IMARC) .  No  pa r t  o f  t h i s  pub l i ca t ion  may  be  
rep roduced ,  repackaged ,  red i s t r i bu ted  o r  res o ld  i n  who le  o r  i n  any  pa r t .  The  pub l i ca t ion  may  a l so  
no t  be  used  i n  any  f o rm o r  by  and means  g raph i c  e lec t ron ic  o r  mechan ic a l ,  i nc lud ing  pho tocopy ing ,  
reco rd ing ,  t ap ing  o r  by  i n fo rmat i on  s to rage  o r  re t r ieva l ,  o r  by  any  o the r  f o rm,  w i t hou t  the  exp ress  
c ons en t  o f  I n t e rna t iona l  Marke t  Ana lys i s  Research  and  Consu l t i ng  ( IMARC) .
Disc la imer :  Al l  con ten ts  and  da ta  o f  t h i s  pub l i c a t i on ,  i nc lud ing  fo recas t s ,  da ta  ana lys i s  and  op in ion  
have  been  based  on  in f o rmat ion  and  sources  be l ieved  to  be  accu ra te  and  re l iab le  a t  t he  t ime  o f  
pub l i sh ing .  In t e rna t i ona l  Ma rke t  Ana l ys is  Research  and  Consu l t ing  makes  no  rep resen ta t ion  o f  
war ran t y  o f  any  k ind  as  to  t he  acc u racy  o r  comp le teness  o f  any  I n fo rmat i on  p rov ided .  IMARC 
accep ts  no  l i ab i l i t y  wha tsoever  f o r  any  los s  o r  damage  resu l t i ng  f rom op in ion ,  e r ro rs  o r  
i naccu rac ies  i f  any  f ound  th is  pub l i ca t ion .
IMARC,  IMARC Group  and  G loba l  Therapy  I ns igh t  Ser i es  a re  reg is t e red  t rademarks  o f  I n te rna t iona l  
Marke t  Ana lys i s  Research  and  Consu l t ing .  A l l  o the r  t rademarks  used  i n  th i s  pub l i ca t i on  a re  
reg i s te red  t rademarks  o f  t he i r  r espec t i ve  compan ies .
Contact Us
Visit us at :
https://www.imarcgroup.com
+1-631-791-1145
[email protected]
Stay With Us: